Ayesha Aman

Dr. Ayesha Aman


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2025 in Open Heart
Verified
Journal Article
Open access
PDF file
AAAyesha Aman
Ayesha Aman
AAArfa Akram
Arfa Akram
BABisma Akram
Bisma Akram
MMMomina Maham
Momina Maham
MBMasooma Zainab Bokhari
Masooma Zainab Bokhari
FYFurqan Yaqub
Furqan Yaqub
Background: Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes. This meta-analysis sought to determine the efficacy of mavacamten and aficamten in hypertrophic cardiomyopathy. Methods: The online databases were searched from inception to July 2024, including the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, ClinicalTrials.gov. The meta-analytical data were pooled using risk ratios (RRs) with 95% CI, standard mean difference (SMD) and SE. Results: A total of 6 randomised controlled trials with 826 hypertrophic cardiomyopathy patients (mean age±SD up to 59.8±14.2 years in intervention vs 60.9±10.5 years in placebo) were included in our study. Of these, 443 received a cardiac myosin inhibitor and 383 received a placebo. The resting left ventricular outflow tract (LVOT) gradient between the two groups was considerably improved by cardiac myosin inhibitors (MD −57.27; 95% CI −63.05 to −51.49). Significant differences were also observed in the post-Valsalva LVOT gradient between the two groups (MD −55.86; 95% CI −65.55 to −46.18). Significantly decreased left ventricle ejection fraction (LVEF) was also seen (MD −4.74; 95% CI −7.22 to −2.26). The New York Health Association (NYHA) class improvement between the two groups also changed significantly (RR 2.21; 95% CI 1.75 to 2.80). Cardiac myosin inhibitors also caused significant improvement in the Kansas City Cardiomyopathy Questionnaire in a Clinical Summary Score between the two groups (MD 7.71; 95% CI 5.37 to 10.05) and significant reduction in the N-terminal pro-B-type natriuretic peptide (SMD −13.27; 95% CI −17.51 to −9.03) and the cardiac troponin I (SMD −11.90; 95% CI −15.07 to −8.72). Conclusion: According to our meta-analysis, cardiac myosin inhibitors significantly improve the resting and post-Valsalva LVOT gradient, reduce the LVEF and improve the NYHA class and cardiac biomarkers when compared with the placebo. PROSPERO registration number: CRD52024586161.

23 January 2026 in Exploration of Cardiology
Verified
Journal Article
Open access
PDF file
AAAyesha Aman
Ayesha Aman
BABisma Akram
Bisma Akram
AAArfa Akram
Arfa Akram
MMMomina Maham
Momina Maham
ETEisha Tariq
Eisha Tariq
MKMalik Waleed Zeb Khan
Malik Waleed Zeb Khan
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (HCM) patients. Methods: From the inception to October 2024, the electronic databases [Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, and ClinicalTrials.gov] were searched. Using a random-effects model and a frequentist framework, specific effect sizes [mean difference (MD) and risk ratio (RR)] were pooled. Results: This network meta-analysis included six randomized controlled trials (RCTs). A total of 826 individuals with HCM were included; 443 of them received a cardiac myosin inhibitor, while 383 received placebo. Comparison of aficamten versus mavacamten through a common comparator, placebo, showed that aficamten caused a lesser decrease in resting LVOT gradient than that of mavacamten [MD = 14.74, 95% CI (3.02; 26.47)]. Therefore, mavacamten ranked higher (P-score = 0.9966) than aficamten (P-score = 0.5034) in decreasing resting LVOT gradient. Aficamten significantly reduced left ventricular ejection fraction (LVEF) in contrast to mavacamten [MD = –5.59, 95% CI (–10.43; –0.75)]. According to P-score ranking, mavacamten (0.5053) ranked higher than aficamten (0.0059). For New York Heart Association (NYHA) class improvement, there was no statistically significant difference between the two groups [MD = –0.37, 95% CI (–1.79; 1.06)]. But P-score ranked mavacamten (0.8466) higher than aficamten (0.6533). Discussion: Mavacamten ranked superior to aficamten in HCM management. However, this ranking is based not on the absolute clinical benefit but on the network point estimates. Additionally, due to a larger body of clinical evidence supporting mavacamten, it has a clear advantage in terms of reliability. Therefore, more direct trials comparing the two drugs would be required to confirm which one is better and provide conclusive evidence.

13 November 2026 in Rheumatology
Verified
Journal Article
Closed access
RFRija Fatima
Rija Fatima
SISaira Iqbal
Saira Iqbal
FAFahad Amin
Fahad Amin
KMKhubaib Tariq Mansoor
Khubaib Tariq Mansoor
ZHZohaib Hassan
Zohaib Hassan
MAMahnoor Ali
Mahnoor Ali
Objectives: Takayasu arteritis (TAK) is a rare chronic granulomatous vasculitis affecting large arteries, causing recurrent disease despite standard treatment. This systematic review and meta-analysis aimed to evaluate efficacy and safety of Janus kinase inhibitors in patients with refractory Takayasu arteritis. Methods: We searched five major databases from inception through July 16, 2026, for observational cohorts, non-randomized interventional studies, and case series including ≥5 patients. Eligible studies enrolled adults with refractory TAK treated with JAK inhibitors. Data were pooled using random-effects models. Risk of bias was assessed using Cochrane ROBINS-I and Joanna Briggs Institute tools. The protocol was registered in PROSPERO (CRD420261469541). GRADE was used to assess certainty of primary efficacy outcomes. Results: Eleven studies comprising 185 patients were included. The pooled clinical remission rate was 64% (95% CI, 55%–72%; I²=0%), while complete and partial remission rates were 65% (95% CI, 55%–74%) and 8% (95% CI, 4%–17%), respectively. Pooled rates of no response and relapse were 24% and 14%, respectively. Imaging improvement or stabilization was observed in 44% of patients, while glucocorticoid-sparing effects occurred in 56%. Adverse events occurred in 10% of patients, and 7% discontinued treatment because of adverse events. GRADE certainty was very low for all assessed outcomes. Conclusion: JAK inhibitors demonstrate promising clinical efficacy and a potentially manageable safety profile in refractory TAK. However, the available evidence is predominantly observational and therefore subject to confounding and other sources of bias. High-quality prospective and randomized studies are needed to establish their efficacy, comparative effectiveness, and long-term safety.